`
`Introduction
`•
`♦ Key Findings
`• Awareness and Trial
`♦ Special Topics
`• Product Perceptions
`♦ Product Usage
`♦ Sales Force
`♦ A
`
`-
`-
`
`Appendix 2: Additional Sales Force Slides
`Appendix 3: Stat Testing Appendix & New Question List
`
`CONYlUJ<.;N'l'lAL
`
`117
`
`SANOFl3 90330923
`
`PTX-0739.0117
`Sanofi Exhibit 2146.117
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Unaided Message Recall (Secondary Message): Total
`(% of physicians recalling)
`Novo Nordisk for Novolog 70130
`
`CONr'lUJ<.;N'l'lAL
`
`Source: COMPASS Sales Force Tracking Study
`Note Data are weighted by reach. Weighted percent of physicians shown for open-ended questions. ME 1 B: In your last discussion with your
`[company] sales representative, what other messages were conveyed regarding [product]? Please be as specific as possible.
`
`164
`
`SANOFl3 90330970
`
`PTX-0739.0164
`Sanofi Exhibit 2146.164
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Treatment Pathway Example - ILLUSTRATION ONLY
`
`CONYlUJ<.;N'l'lAL
`
`197
`
`SANOFl3 90331003
`
`PTX-0739.0197
`Sanofi Exhibit 2146.197
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`Treatment Pathway Example - ILLUSTRATION ONLY
`
`CONYlUJ<.;N'l'lAL
`
`198
`
`SANOFl3 90331004
`
`PTX-0739.0198
`Sanofi Exhibit 2146.198
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`Treatment Pathway Example - ILLUSTRATION ONLY
`
`CONYlUJ<.;N'l'lAL
`
`199
`
`SANOFl3 90331005
`
`PTX-0739.0199
`Sanofi Exhibit 2146.199
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`Treatment Pathway Example - ILLUSTRATION ONLY
`
`CONYlUJ<.;N'l'lAL
`
`200
`
`SANOFl3 90331006
`
`PTX-0739.0200
`Sanofi Exhibit 2146.200
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`